Backed by ARCHIMED, the deal strengthens connected cardiac diagnostics with integrated Holter, ABPM, and telemedicine solutions
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use
The initiative is designed to benefit patients as well as healthcare providers by streamlining access to consultations, diagnostics, and essential care services
The deals, tied to cases in the US District Court for the District of Delaware, effectively extend US patent protection for VYNDAMAX until June 1, 2031
SRM Medical College Hospital and Research Centre hosts undergraduate research expo highlighting innovation, interdisciplinary collaboration, and the role of artificial intelligence
After Phase 3 results show major hair regrowth gains
Subscribe To Our Newsletter & Stay Updated
